The mirage of AI deregulation
By Alondra Nelson,
Science
| 01. 15. 2026
One of the most interventionist approaches to technology governance in the United States in a generation has cloaked itself in the language of deregulation. In early December 2025, President Donald Trump took to Truth Social to announce a forthcoming “One Rule” executive order on artificial intelligence (AI). Trump warned that US leadership in AI would be “DESTROYED IN ITS INFANCY” by the meddling of “50 States, many of them bad actors, involved in RULES and the APPROVAL PROCESS.” But beneath the bluster was a consequential policy move: the federal preemption of state authority to govern AI, framed as the removal of bureaucratic obstacles from the path for American technological dominance.
This social media post and the executive order that soon followed crystallized the prevailing narrative about the administration’s approach to AI governance: that it is fundamentally deregulatory. This narrative is misleading. Not in its particulars—the Trump administration has indeed rescinded Biden-era AI safety and innovation policies and pressured allies to reduce what it calls “innovation-killing regulations”—but in its core framing. To describe this AI policy as “deregulatory” is...
Related Articles
By Evelina Johansson Wilén, Jacobin | 01.18.2026
In her book The Argonauts, Maggie Nelson describes pregnancy as an experience marked by a peculiar duality. On the one hand, it is deeply transformative, bodily alien, sometimes almost incomprehensible to the person undergoing it. On the other hand...
By Daphne O. Martschenko and Julia E. H. Brown, Hastings Bioethics Forum | 01.14.2026
There is growing concern that falling fertility rates will lead to economic and demographic catastrophe. The social and political movement known as pronatalism looks to combat depopulation by encouraging people to have as many children as possible. But not just...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By Nick Paul Taylor, Fierce Biotech | 01.09.2026
Menlo Ventures has made a $16 million bet that the “baby KJ” custom CRISPR therapy success story is repeatable. The funding has enabled CRISPR co-inventor Jennifer Doudna, Ph.D., and baby KJ scientist Fyodor Urnov, Ph.D., to launch Aurora...